

CBNPC stades avancés 2^{ème} ligne ou rattrapage

Références	Promoteur	Design	Sélection	Bras	N pts	R0	SSP (médiane)	Survie			p
								médiane	2 ans	5 ans	
AC anti-PD1											
2015 & 2021 Borghaei (1–4)	Bristol-Myers Squibb	PhIII R (ouverte) « CheckMate 057 »	CBNPC non épi épi prétraité par chimio	nivolumab (3 mg/kg/2 sem)	292	19 %	2,3 m	12,2 m	29 %	13,4 % °	S
				docetaxel 75 mg/m ²	290	12 %	4,2 m	9,4 m	13 %	2,6 % °	
2015 Brahmer (2,3,5)	Bristol-Myers Squibb	PhIII R (ouverte) « CheckMate 017 »	CBNPC épi épi prétraité par chimio	nivolumab (3 mg/kg/2 sem)	135	27 %	3,5 m	9,2m	23 %		S
				docetaxel 75 mg/m ²	137	12 %	2,8 m	6,0 m	15 %		
Wu, 2019 & Lu, 2021(6,7)	Bristol-Myers Squibb	phIIIR « CheckMate 078 »	CBNPC prétraité par chimio	nivolumab (3 mg/kg / 2 sem)	338	17 %	2,8 m	12 m	28 %		S
				docetaxel (75 mg/m ² /3 sem)	166	4 %	2,8 m	9,6 m	18 %		
Waterhouse, 2020 (8,9)	Bristol-Myers Squibb Company et Ono Pharmaceutical	phase IIIb/IV “CheckMate 153”	CBNPC prétraité ayant reçu 1 an de Nivolumab (en progression ou non)	nivolumab 3 mg/kg	127 (tous)			NA	70,4 %		S
					89 (sans progression)		24,7 m	NA	73,4 %		S
				rien	125 (tous)		28, 8 m	56,8 %			
					89 (sans progression)		9,4 m	32,5 m	60,9 %		
Taniguchi, 2022 (10)	Ono Pharmaceutical Co., Ltd et BristolMyers Squibb	PhIII R (ouverte) “TORG1630”	CBNPC prétraité par chimio	Nivolumab	61	14 %	3,1 m	14,7 m			S
				NivolumabpDocetaxel	64	41 %	6,7 m	23,1 m			
AC anti-PDL1											

2016 et 2021 Herbst (11) (12)	Merck & Co	PhIII R (ouverte) « KEYNOTE-010 »	CBNPC prétraité par chimio et avec au moins 1% de cellules PD-L1- positive,	pembrolizumab 2 mg/kg,	345		5,0 m	14,9 m		15,6 %	S
				pembrolizumab 10 mg/kg	346		5,2 m	17,3 m			
				docetaxel 75 mg/m ²	343		4,1 m	8,2 m		8,2 %	
2016 Fehrenbacher (13)	F Hoffmann-La Roche Ltd/Genentech Inc	PhII R « POPLAR »	CBNPC prétraité	atezolizumab 1200 mg	144	14,5 %	2,7 m	12,6 m			S
				docetaxel 75 mg/m ²	143	14,5 %	3,0 m	9,7 m			
2017 Rittmeyer & Von Pawel & Mazières (13–17)	F Hoffmann-La Roche Ltd/Genentech Inc	PhIII R (ouverte) «OAK,,	CBNPC prétraité	atezolizumab 1200 mg	609	14 %	2,8 m	13,8 m	31%		S
				docetaxel	578	13 %	4,0 m	9,6 m	21 %		
2018 Barlesi (18)	Merck et Pfizer	PhIII R (ouverte) «JAVELIN Lung 200 »	CBNPC prétraité par chimio	avelumab 10 mg/kg/2 sem	396	15 %	2,8 m	10,5 m			NS
				docetaxel 75 mg/m ²	306	11 %	4,2 m	9,9 m			
		(analyse sous-groupe PDL1 positif)	PDL1 positif : ≥1% cellules tumorales	avelumab 10 mg/kg/2 sem	264	19 %	3,4 m	11,3 m			NS
				docetaxel 75 mg/m ²	265	12 %	4,1 m	10,4 m			
Levy, 2019 (19)	Celgene Corporation et Merck Sharp & Dohme, Corp	PhIIR	CBNPC prétraité par chimio	pembrolizumab + CC-486 (azacitidine)	51	20 %	2,9 m	11,9 m			NS
				pembrolizumab + placebo	49	14 %	4,0 m	NA			
Combinaison d'agents immunothérapeutiques											
Gettinger, 2021 (20)	SWOG.	Ph III R «Lung-MAP S1400I»	Épi épi prétraité par chimio	Nivolumab 3 mg/kg q2s	127	17 %	2,9 m	11 m	28 %		NS
				Nivolumab idem plus ipilimumab 1 mg/kg q6s	125	18 %	3,8 m	10 m	22 %		

° poolé avec « CheckMate 017 »;

Références

1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. *New England Journal of Medicine*. 22 oct 2015;373(17):1627-39.
2. Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). *Journal of Clinical Oncology*. 10 déc 2017;35(35):3924-33.
3. Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. *Annals of Oncology*. 1 avr 2018;29(4):959-65.
4. Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. *J Clin Oncol*. 15 janv 2021;JCO2001605.
5. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. *New England Journal of Medicine*. 9 juill 2015;373(2):123-35.
6. Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T, et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. *Journal of Thoracic Oncology [Internet]*. mai 2019 [cité 26 déc 2019];14(5):867-75. Disponible sur: <https://linkinghub.elsevier.com/retrieve/pii/S1556086419300206>
7. Lu S, Wang J, Cheng Y, Mok T, Chang J, Zhang L, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). *Lung Cancer [Internet]*. févr 2021 [cité 16 août 2021];152:7-14. Disponible sur: <https://linkinghub.elsevier.com/retrieve/pii/S0169500220306875>
8. Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, et al. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153. *JCO [Internet]*. 20 nov 2020 [cité 24 déc 2020];38(33):3863-73. Disponible sur: <https://ascopubs.org/doi/10.1200/JCO.20.00131>

9. Spigel DR, McCleod M, Jotte RM, Einhorn L, Horn L, Waterhouse DM, et al. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). *J Thorac Oncol*. sept 2019;14(9):1628-39.
10. Taniguchi Y, Shimokawa T, Takiguchi Y, Misumi T, Nakamura Y, Kawashima Y, et al. A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630. *Clinical Cancer Research* [Internet]. 14 oct 2022 [cité 22 mars 2023];28(20):4402-9. Disponible sur: <https://aacrjournals.org/clincancerres/article/28/20/4402/709588/A-Randomized-Comparison-of-Nivolumab-versus>
11. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *The Lancet*. avr 2016;387(10027):1540-50.
12. Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, et al. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. *Lancet Oncol*. janv 2018;19(1):101-14.
13. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet*. 30 avr 2016;387(10030):1837-46.
14. von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, et al. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. *European Journal of Cancer*. janv 2019;107:124-32.
15. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *The Lancet*. janv 2017;389(10066):255-65.
16. von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, et al. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. *European Journal of Cancer* [Internet]. janv 2019 [cité 26 déc 2019];107:124-32. Disponible sur: <https://linkinghub.elsevier.com/retrieve/pii/S0959804918315181>
17. Mazieres J, Rittmeyer A, Gadgeel S, Hida T, Gandara DR, Cortinovis DL, et al. Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. *Journal of Thoracic Oncology* [Internet]. janv 2021 [cité 16 août 2021];16(1):140-50. Disponible sur: <https://linkinghub.elsevier.com/retrieve/pii/S1556086420308029>

18. Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. *Lancet Oncol.* 21 sept 2018;
19. Levy BP, Giaccone G, Besse B, Felip E, Garassino MC, Domine Gomez M, et al. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. *European Journal of Cancer.* févr 2019;108:120-8.
20. Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, et al. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. *JAMA Oncol.* 1 sept 2021;7(9):1368-77.